|
|||||
|
|
Technology evaluation: FluINsure, ID Biomedical |
|
| Authors: | Munoz Flor M |
| Affiliation: | Baylor College of Medicine, Department of Pediatrics, Molecular Virology and Microbiology, BCM-280, Houston, TX 77030, USA. florm@bcm.tmc.edu |
| Abstract: | ID Biomedical (formerly Intellivax International) is developing a trivalent nasal influenza vaccine, FluINsure, for the potential treatment of influenza. The vaccine is currently in phase II clinical trials. |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |